Pharmaceutical care for a case of severe dermal toxicity induced by durvalumab
- VernacularTitle:度伐利尤单抗致重度皮肤毒性反应1例的药学监护
- Author:
Liulian JI
1
;
Zhengbi QIN
2
;
Pengcheng LIU
3
;
Xiaowen DENG
4
;
Lili LIU
4
;
Lijuan YAO
4
;
Tingting LIU
5
;
Pingchen GU
4
Author Information
1. Dept. of Oncology，Yancheng Second People’s Hospital，Jiangsu Yancheng 224000，China
2. Dept. of Humanities and Medical Ethics，School of Medicine，Hubei Minzu University，Hubei Enshi 445000，China
3. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
4. Yancheng Food and Drug Inspection Center （Adverse Drug Reaction Monitoring Center），Jiangsu Yancheng 224000，China
5. Dept. of Pharmacy，Yancheng Second People’s Hospital，Jiangsu Yancheng 224000，China
- Publication Type:Journal Article
- Keywords:
durvalumab;
immune-related cutaneous adverse events;
pharmaceutical care;
immune checkpoint inhibitors
- From:
China Pharmacy
2026;37(1):88-91
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide references for the accurate identification and management of immune-related cutaneous adverse events （irCAEs） caused by durvalumab， and ensuring safe clinical drug use. METHODS Clinical pharmacists participated in the diagnosis and treatment process of a patient with gallbladder cancer who developed irCAEs caused by durvalumab. The clinical pharmacists systematically reviewed the patient’s past medical history and medication history， and assisted physicians in assessing the association between adverse drug reactions and administered drugs. Meanwhile， the clinical pharmacists conducted a graded assessment of the adverse reaction， proposed recommendations such as discontinuing durvalumab and adjusting the administration regimen of glucocorticoids， assisted physicians in restarting immunotherapy， and carried out medication education and other pharmaceutical care. RESULTS The occurrence of irCAEs in this patient was “highly likely” related to durvalumab and was classified as severe. The physicians adopted the clinical pharmacist’s opinion， and after symptomatic treatment， the patient’s skin symptoms improved， and discharged with medication. After the completion of glucocorticoid therapy for the patient， the physician restarted immunotherapy with tislelizumab， and no related adverse reactions occurred again in the patient. CONCLUSIONS Durvalumab can cause irCAEs such as severe skin maculopapular rash. In clinical practice， it is crucial to promptly identify and discontinue suspicious drugs， immediately implement effective symptomatic treatment measures， and actively resume immunotherapy to ensure the continuity and safety of the patient’s treatment.
